Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1993 1
1996 2
1998 1
1999 1
2000 2
2001 1
2003 1
2005 1
2006 2
2009 2
2010 2
2011 4
2012 5
2013 2
2014 2
2015 3
2016 8
2017 12
2018 9
2019 10
2020 9
2021 7
2022 10
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Champiat S, et al. Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28. Ann Oncol. 2016. PMID: 26715621 Free article. Review.
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers. Therefore, their use will not be limited anymore to selected …
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of …
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. J Clin Invest. 2019 Jul 30;129(10):4492-4505. doi: 10.1172/JCI128212. J Clin Invest. 2019. PMID: 31361600 Free PMC article.
Our analyses revealed five mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: (i) AR-high tumors (ARPC), (ii) AR-low tumors (ARLPC), (iii) amphicrine tumors composed of cells co-expressin …
Our analyses revealed five mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (N …
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Kazemi MH, et al. Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022. Front Immunol. 2022. PMID: 36389779 Free PMC article. Review.
Gaining favorable outcomes following TIL therapy of patients with metastatic melanoma, cervical cancer, ovarian cancer, and breast cancer has raised hope in patients with refractory solid tumors, too. ...Herein, we reviewed the recent advances in the TIL t …
Gaining favorable outcomes following TIL therapy of patients with metastatic melanoma, cervical cancer, ovarian cancer, and breast ca …
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.
Huuhtanen J, Kasanen H, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S. Huuhtanen J, et al. J Clin Invest. 2023 Mar 15;133(6):e164809. doi: 10.1172/JCI164809. J Clin Invest. 2023. PMID: 36719749 Free PMC article.
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.MethodsWe eva …
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approve …
The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy.
Clifton-Bligh RJ. Clifton-Bligh RJ. Rev Endocr Metab Disord. 2023 Feb;24(1):49-56. doi: 10.1007/s11154-022-09773-2. Epub 2023 Jan 13. Rev Endocr Metab Disord. 2023. PMID: 36637675 Free PMC article. Review.
Since optimal outcomes are only achieved by early recognition of PPGL in (or ideally before) pregnancy, it is incumbent for clinicians to be aware of this diagnosis in a pregnant woman with hypertension occurring before 20 weeks' gestation, and acute and/or refractory hype …
Since optimal outcomes are only achieved by early recognition of PPGL in (or ideally before) pregnancy, it is incumbent for clinicians to be …
The Evolving Treatment Landscape of Merkel Cell Carcinoma.
Singh N, McClure EM, Akaike T, Park SY, Huynh ET, Goff PH, Nghiem P. Singh N, et al. Curr Treat Options Oncol. 2023 Sep;24(9):1231-1258. doi: 10.1007/s11864-023-01118-8. Epub 2023 Jul 5. Curr Treat Options Oncol. 2023. PMID: 37403007 Review.
The patient population is generally older, with comorbidities. Multidisciplinary and personalized care is therefore paramount, based on patient preferences regarding risks and benefits. ...Cytotoxic chemotherapy is sometimes used for debulking disease or in patients who ca …
The patient population is generally older, with comorbidities. Multidisciplinary and personalized care is therefore paramount, based …
Recent Advances in the Diagnosis and Management of Carcinoid Syndrome.
Subash N, Papali MM, Bahadur KP, Avanthika C, Jhaveri S, Thannir S, Joshi M, Valisekka SS. Subash N, et al. Dis Mon. 2022 Jul;68(7):101304. doi: 10.1016/j.disamonth.2021.101304. Epub 2021 Dec 28. Dis Mon. 2022. PMID: 34972546 Review.
Carcinoid syndrome, a paraneoplastic condition linked with the release of multiple humoral factors, affects around 30-40% of patients with well-differentiated neuroendocrine tumours. Carcinoid syndrome has a major and unfavourable impact on patients' quality of life; it ra …
Carcinoid syndrome, a paraneoplastic condition linked with the release of multiple humoral factors, affects around 30-40% of patients with w …
Multidisciplinary management of refractory insulinomas.
Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Brown E, et al. Clin Endocrinol (Oxf). 2018 May;88(5):615-624. doi: 10.1111/cen.13528. Epub 2018 Mar 2. Clin Endocrinol (Oxf). 2018. PMID: 29205458 Review.
This review considers the developments in the medical and other nonsurgical management options for cases refractory to standard medical management. Early referral to a dedicated neuroendocrine multidisciplinary team is critical considering the array of medical, onco …
This review considers the developments in the medical and other nonsurgical management options for cases refractory to standard medic …
Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A, Naruse M. Tanabe A, et al. Hypertens Res. 2020 Nov;43(11):1141-1151. doi: 10.1038/s41440-020-0531-0. Epub 2020 Aug 11. Hypertens Res. 2020. PMID: 32778780 Review.
Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that cause refractory hypertension and hypertensive crisis. ...Currently, PASS or GAPP histological scores and SDHB immunostaining are clinically used to attempt to discriminate benign from malignant tu …
Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that cause refractory hypertension and hypertensive crisis. ...Cu …
High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?
Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. Alonso-Gordoa T, et al. Curr Treat Options Oncol. 2022 Jul;23(7):1001-1013. doi: 10.1007/s11864-022-00983-z. Epub 2022 May 1. Curr Treat Options Oncol. 2022. PMID: 35501552 Review.
Neuroendocrine tumors (NET) represent a complex and heterogeneous group of malignancies arising from the diffuse endocrine cells and other cells derived from the neural crest. ...Unfortunately, most patients will eventually develop resistance to SSA treatment by dif …
Neuroendocrine tumors (NET) represent a complex and heterogeneous group of malignancies arising from the diffuse endocrine cel …
97 results